16.4
Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing…
Modified-release or MR dosage forms are designed to prolong drug release and maintain steady plasma drug levels, minimizing fluctuations compared to conventional-release formulations and improving therapeutic outcomes.
Their bioavailability is typically under 100% due to incomplete drug release, prolonged absorption phases, and first-pass metabolism in orally administered drugs.
So, studying the in vivo bioavailability of MR formulations is crucial. These studies measure the fraction of drug absorbed, potential dose dumping, and the effects of food and circadian rhythms on drug absorption. Single-dose studies evaluate absorption, while multiple-dose studies assess sustained therapeutic levels, steady-state concentration ratios, and percent fluctuation.
Immediate-release formulations, and in some cases oral solutions or suspensions, serve as reference standards for comparison when evaluating MR products.
Additionally, in vitro bioequivalence tests simulate in vivo conditions to assess drug release profiles. This uses biorelevant dissolution media, considering variations in gastrointestinal pH, fed versus fasted states, and the presence of digestive secretions.
View the full transcript and gain access to JoVE Core videos
Q1: Why is bioavailability typically below 100% for modified-release formulations?
Modified-release formulations have bioavailability below 100% due to incomplete drug release, prolonged absorption phases, and first-pass metabolism in orally administered drugs. Additionally, limitations in drug permeability across the gastrointestinal epithelium restrict the fraction of drug reaching systemic circulation, reducing overall bioavailability compared to conventional formulations.
Q2: What is dose dumping and why is it evaluated in single-dose bioavailability studies?
Dose dumping refers to the unintended rapid release of drug that could lead to toxicity. Single-dose studies evaluate absorption profiles and detect dose dumping risk by measuring maximum plasma concentration (Cmax), time to reach Cmax (tmax), and area under the concentration-time curve (AUC), which reflects total drug exposure.
Q3: How do multiple-dose studies differ from single-dose studies in assessing modified-release formulations?
Multiple-dose studies assess the formulation's ability to maintain sustained therapeutic levels over extended periods, determining steady-state plasma concentrations where drug administration rate equals elimination rate. They evaluate steady-state concentration ratios and percentage fluctuation to minimize peaks and troughs, reducing side effects and enhancing therapeutic efficacy.
Q4: What factors does in vitro bioequivalence testing simulate to predict modified-release drug performance?
In vitro bioequivalence tests simulate gastrointestinal conditions using biorelevant dissolution media that account for pH variations, fed versus fasted states, and the presence of bile or pancreatic secretions. These assessments predict in vivo performance and ensure formulations meet regulatory bioequivalence criteria before advancing to clinical testing.
Q5: What reference standards are used when comparing modified-release formulations?
Modified-release formulations are compared to reference standards such as oral solutions, suspensions, or existing modified-release products with well-established pharmacokinetics. Immediate-release formulations serve as primary reference standards for evaluating modified-release products. These comparisons ensure consistent bioavailability and therapeutic performance across formulations.
Q6: How do food and circadian rhythms affect modified-release drug bioavailability?
In vivo bioavailability studies measure the effects of food and circadian rhythms on drug absorption in modified-release formulations. These factors influence gastrointestinal pH, transit time, and digestive secretion levels, which can alter drug release profiles and absorption rates, affecting therapeutic outcomes and plasma concentration fluctuations.
Q7: Why are both in vivo and in vitro assessments necessary for optimizing modified-release formulations?
Integrating in vivo bioavailability studies with in vitro bioequivalence assessments enables researchers to optimize modified-release formulations for consistent drug release and improved therapeutic outcomes. In vitro tests predict in vivo performance, while in vivo studies confirm actual bioavailability, minimizing variability in patient response and ensuring regulatory compliance.